医学
舒尼替尼
酪氨酸激酶抑制剂
内科学
血小板源性生长因子受体
索拉非尼
癌症研究
肿瘤科
耐受性
酪氨酸激酶
成纤维细胞生长因子受体
生长因子受体
血液学
癌症
药理学
成纤维细胞生长因子
受体
生长因子
不利影响
肝细胞癌
作者
Guoshuang Shen,Fangchao Zheng,Dengfeng Ren,Feng Du,Qiuxia Dong,Ziyi Wang,Fuxing Zhao,Raees Ahmad,Jiuda Zhao
标识
DOI:10.1186/s13045-018-0664-7
摘要
Anlotinib is a new, orally administered tyrosine kinase inhibitor that targets vascular endothelial growth factor receptor (VEGFR), fibroblast growth factor receptor (FGFR), platelet-derived growth factor receptors (PDGFR), and c-kit. Compared to the effect of placebo, it improved both progression-free survival (PFS) and overall survival (OS) in a phase III trial in patients with advanced non-small-cell lung cancer (NSCLC), despite progression of the cancer after two lines of prior treatments. Recently, the China Food and Drug Administration (CFDA) approved single agent anlotinib as a third-line treatment for patients with advanced NSCLC. Moreover, a randomized phase IIB trial demonstrated that anlotinib significantly prolonged the median PFS in patients with advanced soft tissue sarcoma (STS). Anlotinib also showed promising efficacy in patients with advanced medullary thyroid carcinoma and metastatic renal cell carcinoma (mRCC). The tolerability profile of anlotinib is similar to that of other tyrosine kinase inhibitors that target VEGFR and other tyrosine kinase-mediated pathways; however, anlotinib has a significantly lower incidence of grade 3 or higher side effects compared to that of sunitinib. We review the rationale, clinical evidence, and future perspectives of anlotinib for the treatment of multiple cancers.
科研通智能强力驱动
Strongly Powered by AbleSci AI